Overall rank by patents
#41,661
Across all tracked assignees
USPTO PatentsView assignee record - 6 granted patents across 7 technology areas, active 2022–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: F25D (REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR).
The verdict
MVE holds 6 US patents across 7 technology areas, rank #41,661 of 50,000 tracked assignees.
MVE Biological Solutions US, Llc has been granted 6 US utility patents between 2022 and 2025, placing MVE Biological Solutions US, Llc at rank #41,661 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.3 claims per patent with primary concentration in F25D (REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR). As a US Corporation, MVE Biological Solutions US, Llc is one of the more focused assignees in the PatentsView dataset. By volume, MVE sits between Murata Integrated Passive Solutions (6 patents, rank #41,657) and Mytee Products Inc. (6 patents, rank #41,665) - the closest US assignees by grant volume. The composite Innovation Score of 47.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2025, with 6 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. MVE Biological Solutions US, Llc's 18.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark MVE Biological Solutions US, Llc against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
MURATA INTEGRATED PASSIVE SOLUTIONS
6 patents
MUSIC GROUP IP LTD
6 patents
MUTOH INDUSTRIES LTD.
6 patents
MUTRONICS CO., LTD
6 patents
MWI Veterinary Supply Co.
6 patents
MY-SEMI INC.
6 patents
MYFC AB
6 patents
MYTEE PRODUCTS INC.
6 patents
MVE Biological Solutions US, LLC
6 patents
What this shows MVE holds 6 patents at rank #41,661, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #41,661 in granted patent volume.
Other assignees with the most granted patents in MVE's primary technology class.
MVE's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
47 Top 19% higher than 81% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 2 | 33.3% |
| 2023 | 1 | 16.7% |
| 2024 | 2 | 33.3% |
| 2025 | 1 | 16.7% |
Top 7 of 7 technology areas
Overall rank by patents
#41,661
Across all tracked assignees
47.1 out of 100
How to use this portfolio
MVE's 6 grants land it in the top 19% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.